Aug. 26 at 7:24 PM
$IRWD
LINZESS is doing really well for them, net sales of
$282 million in the latest quarter, of which IRWD was eligible to attribute
$110 million to itself.
Same time, they´ve raised their full-year revenue forecast for LINZESS U.S. net sales from a range of between
$1.125 and
$1.175 billion to a range of
$1.15 and
$1.2 billion.
Revenue forecast has also been raised by from
$450 to
$475 million to
$460 to
$485 million
also increasing its expected adjusted EBITDA from >
$300 million to >
$310 million.
This doesn´t look bad except for the fact that LINZESS goes off patent, with Teva already having an agreement to launch a generic version72 mcg dose March 2029, with patents for the 145 mcg+ 290 mcg doses expected to launch in early 2030.
Other than LINZESS, IRWD only has 1 other product, still in clinical development,recently started recruiting for its PH3 confirmatory trial. PH3 data already looked good: significant reduction in relative weekly PS volume from baseline.
https://seekingalpha.com/article/4940450-ironwood-pharmaceuticals-high-dependence-on-its-next-trial
